We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futuragene | LSE:FGN | London | Ordinary Share | GB0031791782 | ORD 0.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 89.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/5/2009 20:18 | see the april RNS on CBD tech and patent granted. "Dr. Stanley Hirsch, Group CEO of FuturaGene said "This patent consolidates our global intellectual property position in the critical area of cell wall modification, which is a fundamental technology for yield enhancement in plants. This is highly significant for the sustainable industrial forestry, biofuel and biopower sectors. Japan is home to some of the world's largest pulp and paper producers, enhancing the significance of this patent." saffy.. | safman | |
08/5/2009 09:09 | it looks good short term certainly, good fundraising @ a very good price. The sector is what is good for medium to longer term investment, and i think certainly a good case for FGN, now internal matters have been resolved. saffy.. | safman | |
08/5/2009 07:17 | Great stock with great future | moosley | |
08/5/2009 03:22 | It's amazing how ignored this share is.... | mcsean2164 | |
16/2/2009 09:01 | Certainly going in the right direction :) | leadersoffice | |
27/1/2009 22:38 | Good run on settling of litigation ... now profit taking ... renewed bull run may have to wait for some news. That is my take. | red ninja | |
27/1/2009 13:35 | any reason for this stumble ?? lost alot today so far | donn84 | |
18/1/2009 20:58 | I wonder how high it will go this time ... | red ninja | |
16/1/2009 09:38 | Sold out today. Company still looks good but given the performance of the rest of my portfolio it's time to put something aside! Small investment but nice to see a 150% return.... | mcsean2164 | |
07/1/2009 21:27 | Interesting article on GM potatoes in China, slightly o/t but worth a read Why China? China should be considered a potential market for GM potatoes for several reasons. First, China currently has almost 1.3 billion people and is likely to exceed 1.4 billion by 2050 (Population Reference Bureau, 2002). China recognizes that if it is going to continue to feed its people, it must find more efficient agricultural production methods. To this end, China is spending close to $120 million each year on biotech research. In fact, China is the fourth largest producer of GM crops in the world after the US, Canada, and Argentina, and has approved more than a dozen genetically modified crops for development (Huang, Rozelle, Pray, & Wang, 2001). | mcsean2164 | |
07/1/2009 16:52 | Sorry to say I am now in and that usually means the share price goes down!!!! | simon102 | |
07/1/2009 11:23 | up again .. well done to those that bought below 10p.. saffy.. | safman | |
06/1/2009 18:54 | Still going, and certainly in the right sector for me .. saffy.. | safman | |
06/1/2009 16:53 | Nice rise. Looking good... lets hope it can keep it up. Im holding since 90p. | leadersoffice | |
01/1/2009 23:48 | From The Times January 1, 2009 FuturaGene prospects rise Smaller companies Peter Stiff Shares in FuturaGene soared by more than 30 per cent yesterday after the biotechnology group with a focus on agriculture cleared the decks for the new year by settling all legal claims with its founders. The group, which is developing technology to genetically engineer plants to better withstand cold and drought, as well as making trees grow more quickly, has resolved all claims with a group of eight founders connected to the company's origins as a university spin-off. The terms of the settlement have not been disclosed. FuturaGene has also reached an out-of-court settlement with Bruno Ruggiero, its former chief executive, regarding alleged wrongful dismissal. Moreover, the group will now not pay out any more shares to the founders, effectively clearing a stock overhang. The disputes were sparked when the group parted company with Mr Ruggiero in 2006. Mark Pritchard, FuturaGene's chairman, said that the resolution of the company's legal issues left it clear to showcase its technology in 2009. The shares rose 7p to 29p. | johnlll | |
01/1/2009 11:29 | some people expect the earth ! | leadersoffice | |
31/12/2008 17:32 | Sorry coulden't resist and took profits today.Was hoping for product commercialisation update as well as news about litigation which we all knew about last week. Will buy back if profit taking comes about,at perhaps a more advantageous price...happy new year to all. | harmoye | |
31/12/2008 07:09 | Settlement of Litigation (Futuragene) RNS Number : 9256K Futuragene PLC 31 December 2008 FUTURAGENE PLC ("FuturaGene" or the "Company") Settlement of Litigation 31st December 2008 The Board of FuturaGene ("the Board") announces that it has settled all of the existing legal claims between the Company and certain founders, namely B. Ruggiero, F. Ruggiero, M. Zgagacz, R. Bressan, H. Bohnert, J. Zhu, V. Agnohotri and A. Agnohotri. Accordingly, as of today, all claims among these parties have been resolved. Although the specific terms of the settlement are confidential, pursuant to AIM Rule 12 the Company makes the following disclosures: - All parties have terminated all lawsuits against each other. - The Company has not issued, nor will it issue in the future, any additional shares to B. Ruggiero, F. Ruggiero, M. Zgagacz, R. Bressan, H. Bohnert, J. Zhu, V. Agnohotri and A. Agnohotri. - The Company has reached an out of court settlement with Mr B. Ruggiero in respect of the wrongful dismissal case, without any admission of wrong doing - The Company has requested that a license to a discovery known as Osmotin be transferred back to Purdue Research Foundation ("PRF"). Osmotin was licensed by FuturaGene, Inc. from PRF in April, 2005. The Company does not deem Osmotin material for its business. For further information, please contact: FuturaGene Plc Mark Pritchard, Chairman +44 (0) 7802 827 846 FuturaGene Plc Dr Stanley Hirsch, CEO + 972 544 562 724 Evolution Securities Neil Elliot +44 (0) 20 7071 4300 This information is provided by RNS The company news service from the London Stock Exchange END MSCWUGQAPUPRP | leadersoffice | |
24/12/2008 11:52 | Well we can see litigation problem being solved. Just as a matter of interest before the trouble with the ex ceo the share price was 150p when ex ceo suspension announced. We know that the ex ceo is buying big time now.FuturaGene must have something very valuable that the ex ceo wants slice of.Wonder if the share price will head back up to 150p again when litigation sorted?..have a great Christmas all. | harmoye | |
23/12/2008 16:34 | Well done saffy, wait and see now but looking good. | harmoye | |
23/12/2008 16:10 | RNS Number : 7211K Futuragene PLC 23 December 2008 Futuragene Plc (the 'Company') Share Price Movement The directors of the Company note the recent share price rise. The Company has advanced in negotiations regarding a settlement to the litigation with Bruno Ruggiero and Marta Zgagazc, respectively the former CEO and COO of FuturaGene, and Messrs Bressan, Zhu and Bohnert, all former members of the Scientific Advisory Board of the Company, D-Helix Inc. and D-Helix Indiana, Inc. The Company will make further updates as appropriate. 23 December 2008 This information is provided by RNS The company news service from the London Stock Exchange END STRBLBDDUGDGGIX and the holdings RNSs.. saffy.. | safman | |
23/12/2008 15:11 | Appreciated saffy and the same to you my friend | harmoye | |
23/12/2008 13:47 | yep, there were some big trades earlier on last week.. should see an RNS, but certainly v. interested in the technology.. best of luck.. saffy.. | safman |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions